Top Tweets for #affimer
@avacta #AVCT #Affimer Next generation biotherapeutics to surpass limitations of #CancerTherapies @LGChemRnD
Nice to see work with @Tomlinson_lab & others showing labelling of estrogen receptor with an Affimer published @BiophysJ Adds to growing recognition of Affimers as antibody-replacement tools. Have a look: https://t.co/6Y5Qhxqbil
#estrogenreceptor #Affimer
Affimer applications in AMR at #ASMicrobe. Poster sessions AAR314 today and AAR372 tomorrow in the exhibition hall! #ASM #Affimer @Tomlinson_lab @UniversityLeeds
#Avacta (AIM: AVCT) #AVCT $AVCT $AVCTF clinical state with two platforms #Affimer (diagnostics + therapeutics) and preCISION (#cancer ) AVA6000 in P1 trials is the key near-term value driver. #ACFResearch Core Investment Case https://t.co/NNC7T4EQ4f #oncology @avacta @OTCMarkets
#Avacta (AIM: AVCT) #AVCT $AVCT $AVCTF clinical state with two platforms #Affimer (diagnostics + therapeutics) and preCISION (#cancer ) AVA6000 in P1 trials is the key near-term value driver. #ACFResearch Core Investment Case https://t.co/i2k2wslWRI #oncology @avacta @OTCMarkets
#AVCT LSE: $AVCT transferred #intellectualproperty relating to #Affimer® proteins against 1st target into #AffyXell = agreed milestone in JV agrmnt w/ #DaewoongPharmaceutical. #ACFInsight https://t.co/PBfHb26S8r #oncology @avacta
6.F) targeted drug-loaded cubosomes showed a 5–7-fold higher drug accumulation in the tumor tissue compared to the liver, kidneys, and other vital organs, a significant decrease in tumor growth
#avct #affimer #avacta #cubosomes
5.D) exhibiting low nonspecific absorption and toxicity in other vital organs
E) Cancerous spheroids had maximum cell death compared to noncancerous cells upon targeted delivery
#avct #affimer #avacta #cubosomes
#2.A must read article released yesterday (23rd Feb 2022), outlining the first preclinical investigation of Affimer targeted cubosomes as a cancer therapeutic!
https://t.co/ZwLDPY8Rkd
#avct #affimer #avacta #cubosomes
#1.Affimer Tagged Cubosomes (drug delivery vehicles) as a cancer therapeutic!
Cubosomes are porous lyotropic liquid crystalline nanoparticles that have shown great premise as drug delivery vehicles.
#avct #affimer #avacta #cubosomes
@TheEthicalTout How can @avacta be so undervalued? The progress made and the work completed over two years is incredible. This will one day be one of the UK’s most exciting #biotech companies.
What an opportunity for #investing 🇬🇧 #cancer treatments using targeted #chemotherapy #affimer tech!
Interesting keynote presentation on "novel and emerging imaging approaches" by Prof Michelle Peckham,
@UniversityLeeds, discussing the advantages of Affimer proteins. @Avacta commercialises #Affimer technology, developing novel #cancer #immunotherapies and #diagnostics.
@IngoHeuschkel @ZiikZiiii Here’s one of the, if not THE best performing lateral flow test in the world. #AVCT #DeltaVariant #affimer
https://t.co/KfcCoEXf11
Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase 1 Clinical Trial. https://t.co/qkRNKQj8p0 #AVCT
@JimBethell as our Lord of innovation, isn't it a real 'no brainer' to back the #AVCT #affidx LFT over all others as doing so will fund the commercialisation of highly excting UK owned #affimer technology ensuring it remains in UK hands with potential to deliver global dominance
@Ophidian18 @chrischirp The great shame is that UK Gov WASTED 3b with Innova. Just imagine what that money could have generated for the UK if it had been invested in UK based TECHNOLOGY E. G. #affimer #AVCT and powered the therapeutic business, creating a global UK powerhouse
#affimer tech reaching targets that have until now been untouchable in cancer therapeutics. This is why #AVCT is way bigger than just covid testing. The affimers are the key to the buyout that will eventually come.
#Cancer #RashmikaMandanna
1/2
Amy Turner, co-author: "RAS really is the Holy Grail of therapeutic targets. The fact that it has previously been termed 'undruggable' has allowed us to demonstrate the huge impact that our Affimer technology can have when it comes to treating challenging pathologies."
2/5
Two proprietary platforms (#Affimer & #PreCISION) with multiple applications provide @avacta with several attractive opportunities in #diagnostics &, longer-term, in #therapeutics.
Read our $AVCT.L initiation, So much more than a play on #COVIDtesting: https://t.co/c2CZdrFPic
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.3M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.7M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.7M followers
KATY PERRY
@katyperry
87.2M followers
Taylor Swift
@taylorswift13
81M followers
Lady Gaga
@ladygaga
72.6M followers
Kim Kardashian
@kimkardashian
69.6M followers
Virat Kohli
@imvkohli
69.2M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.6M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.8M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.3M followers